



---

19 June - 23 June 2023

## News

---

### New platform for oncologist MedEd 21.06.2023 AM

Posted 21 June 2023 AM

**Pharma has a key role to play in helping cancer specialists meet their professional development requirements - and a new digital platform could help that partnership grow further.**

The Private Cancer Physicians of Australia (PCPA) has announced the launch of a new digital platform, CPD4MedProfessional.com, which will help cancer specialists meet their updated continuing professional development (CPD) requirements.

The new online support program has been developed with the PCPA's education partners ScienceToLife.

Currently seven pharma companies are part of the PCPA Strategic Alliance Partnership program, supporting educational activities that help medical and radiation oncologists and haematologists meet their continuing professional development (CPD) requirements.

Roche, AstraZeneca, MSD, Gilead, Servier, Merck and Kite Pharma are already supporting cancer clinicians through the program, along with GenesisCare.

Pharma is uniquely placed to support the program's educational opportunities that centre around drug development and the application of treatments.

Past activities involving pharma have included a Cancer Patient Management [podcast series](#), and an immersive two-day [masterclass](#) curated by PCPA for Gilead and several executives.

#### Efficiency

The updated CPD requirements have caused confusion since coming into force five months ago. Now, when cancer specialists attend or tune into educational events via the online support program, their attendance will contribute to their 50 hours of CPD, a requirement set by the Medical Board of Australia.

President of the PCPA, Associate Professor Christopher Steer, said the new portal will help cancer specialists better serve their patients.

"As clinicians, we believe in surpassing world-class standards in our ongoing personal development and training but these new hour-based rules are demanding, to say the least," Steer said.

"We knew there must be a more efficient way to navigate these new rules, especially for members working in the private cancer-care system.

"We are listening, and responding, to the needs of our members so they, in turn, can continue to prioritise the needs of their cancer patients."

**Trudie McConnochie**

---

#### Don't miss out

If you were passed this article by a colleague, chances are you've missed other important **Pharma in Focus** articles and features.

To find out more, go to [www.pharmainfocus.com.au](http://www.pharmainfocus.com.au) and sign up for a **FREE Full Text trial**

---

**Pharma in Focus**

*Australia's most trusted source of pharma news*

© Copyright Lush Media. End of News - printed 21 June 2023